Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biosion USA to Start US Phase II Trials of Novel Candidate for Asthma

publication date: Apr 5, 2023

Biosion USA was given the green light to begin a US Phase II trial of its lead asset, BSI-045B, an anti-TSLP mAb, to treat atopic dermatitis, severe asthma and other eosinophilic and Th2 immune-related diseases. Biosion Inc., the parent company, is located in Nanjing and Delaware. In a Phase I trial, BSI-045B showed it could become a first-in-class treatment for AD based on its single dose activity in AD patients. Biosion out-licensed China rights for BSI-045B to CTTQ, a Sino Biopharm subsidiary, that is currently in a China Phase II trial for severe asthma. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital